Details for Patent: 3,520,926

Summary for Patent: 3,520,926

Title:	Methylhydrazinomethyl-substituted benzoic acid amides
Abstract:
Inventor(s):	Werner Bollag, Hugo Gutmann, Balthasar Hegedus, Ado Kaiser, Albert Langemann, Marcel Muller, Paul Zeller
Assignee:	F Hoffmann La Roche AG , Hoffmann La Roche Inc
Application Number:	US593734A
Patent Claim Types: see list of patent claims

What Is US Patent 3,520,926 and What Claims Define Its Legal Scope?

US Patent 3,520,926 is a granted United States drug patent with a defined set of claims that establish the legal scope of protection. However, the claim text is not included in the input (“The claims are: …” stops without providing the actual claim language). Without the claim text (and without specific bibliographic context such as the patent title, assignee, and filing/publication dates), a complete and accurate analysis of:

• Scope by claim construction (independent and dependent claim limitations),
• Potential design-around surfaces (what features are claimed vs. unclaimed),
• Validity and enforceability posture by comparing claim elements to known prior art,
• Landscape mapping across competing US filings and continuations,
• Term and expiration logic (including any patent term adjustment extensions),

cannot be produced in a way that is faithful to the legal record.

No further analysis can be generated from the provided information.

---

Key Takeaways

• US Patent 3,520,926 can only be analyzed for legal scope and patent landscape using the actual claim language and patent bibliographic record.
• The prompt does not include the claims, so a complete and accurate scope/claims/landscape analysis cannot be produced.

---

FAQs

1. What determines the scope of a drug patent in the US? The exact limitations in the independent claims, interpreted in light of the specification and prosecution history, define the scope.
2. Do dependent claims narrow or broaden protection? Dependent claims narrow protection by adding additional limitations; they also create separate infringement hooks if their added features are satisfied.
3. How do you evaluate a patent landscape for a specific patent number? You map related filings by same assignee, same compound/class, and close claim element overlap, then compare to citing documents and later grant/abandonment outcomes.
4. What role do prior art and obviousness play? Novelty and non-obviousness depend on whether claim elements are disclosed or would have been obvious in combination at relevant priority dates.
5. How is patent expiration determined? Base term runs from the earliest effective filing date, adjusted by prosecution history and any statutory adjustments/extensions where applicable.

---

References

[1] No sources were provided in the prompt.

Drugs Protected by US Patent 3,520,926

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 3,520,926

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Belgium	618638
Switzerland	441366
Cyprus	314
Denmark	120758
Denmark	120902
United Kingdom	968460